Bioavailability of recombinant human growth hormone in different concentrations and formulations.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Conventional growth hormone-therapy was withdrawn 2 days before each study period.

Blood samples were drawn over a 24-hr period and assessed for growth hormone, serum insulin-like growth factor I (IGF-I), insulin and glucose.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Whether the bioavailability of growth hormone depends on the concentration or formulation of the preparation was evaluated in 18 growth hormone-deficient patients.

How the Study Was Run

The design is described as randomized, single-blind and crossover.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

In this single-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study one party knew the assignments and the other did not.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

What Was Measured

Blood samples were drawn over a 24-hr period and assessed for growth hormone, serum insulin-like growth factor I (IGF-I), insulin and glucose.

PubMed files the paper under topics including Absorption, Benzyl Alcohol, Benzyl Alcohols, Biological Availability, Blood Glucose, Buffers and Denmark.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1996 (Pharmacology & toxicology), a journal based in Denmark.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.